The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
Open accessAbstract
Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality rate. Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patient’s post-operative survival but most cases eventually demonstrate resistance to TMZ. O6-methylguanine-DNA methyltransferase (MGMT) repairs the main cytotoxic lesion, as O6-methylguanine, generated by TMZ, can be the main mechanism of the drug resistance. In addition, mismatch repair and BER also contribute to TMZ resistance. TMZ treatment can induce self-protective autophagy, a mechanism by which tumor cells resist TMZ treatment. Emerging evidence also demonstrated that a small population of cells expressing stem cell markers, also identified as GBM stem cells (GSCs), contributes to drug resistance and tumor recurrence owing to their ability for self-renewal and invasion into neighboring tissue. Some molecules maintain stem cell properties. Other molecules or signaling pathways regulate stemness and influence MGMT activity, making these GCSs attractive therapeutic targets. Treatments targeting these molecules and pathways result in suppression of GSCs stemness and, in highly resistant cases, a decrease in MGMT activity. Recently, some novel therapeutic strategies, targeted molecules, immunotherapies, and microRNAs have provided new potential treatments for highly resistant GBM cases. In this review, we summarize the current knowledge of different resistance mechanisms, novel strategies for enhancing the effect of TMZ, and emerging therapeutic approaches to eliminate GSCs, all with the aim to produce a successful GBM treatment and discuss future directions for basic and clinical research to achieve this end.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.350 · Cited by 1,204
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells
Piccirillo, S. G. M., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., & Vescovi, A. L. (2006) · Nature · doi:10.1038/nature05349 · Cited by 1,176
Temozolomide resistance in glioblastoma multiforme
Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,163
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles.
Paglin, S., Hollister, T. C., Delohery, T. M., Hackett, N., McMahill, M., Sphicas, E., Domingo, D., & Yahalom, J. (2001) · PubMed · Cited by 952
The Sox Family of Transcription Factors: Versatile Regulators of Stem and Progenitor Cell Fate
Sarkar, A., & Hochedlinger, K. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.007 · Cited by 920
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Wnt/β-catenin signaling in cancer stemness and malignant behavior
Fodde, R., & Brabletz, T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.007 · Cited by 785
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Mao, P., Joshi, K., Li, J., Kim, S.-H., Li, P., Santana-Santos, L., Luthra, S., Chandran, U. R., Benos, P. V., Smith, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221478110 · Cited by 642
Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry
Seki, A., Coppinger, J. A., Jang, C.-Y., Yates, J. R., & Fang, G. (2008) · Science · doi:10.1126/science.1157425 · Cited by 619
Sox proteins: regulators of cell fate specification and differentiation
Kamachi, Y., & Kondoh, H. (2013) · Development · doi:10.1242/dev.091793 · Cited by 572
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J.-W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543
Wnt signaling in stem and cancer stem cells
Holland, J. D., Klaus, A., Garratt, A. N., & Birchmeier, W. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.01.004 · Cited by 504
Hippocampal development and neural stem cell maintenance require Sox2-dependent regulation of Shh
Favaro, R., Valotta, M., Ferri, A. L. M., Latorre, E., Mariani, J., Giachino, C., Lancini, C., Tosetti, V., Ottolenghi, S., Taylor, V., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2397 · Cited by 498
Yip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 400
Maycotte, P., & Thorburn, A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14627 · Cited by 393
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.139 · Cited by 388
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Filley, A. C., Henriquez, M., & Dey, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21586 · Cited by 386
Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 367
Autophagy: a barrier or an adaptive response to cancer
Ogier-Denis, E., & Codogno, P. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00004-0 · Cited by 365
Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells
Marumoto, T., Honda, S., Hara, T., Nitta, M., Hirota, T., Kohmura, E., & Saya, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306275200 · Cited by 362
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.
Li, D., Zhu, J., Firozi, P. F., Abbruzzese, J. L., Evans, D. B., Cleary, K. R., Friess, H., & Sen, S. (2003) · PubMed · Cited by 335
Hirose, Y., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 333
Immune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Sanchez, A. M., Csibi, A., Raibon, A., Cornille, K., Gay, S., Bernardi, H., & Candau, R. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23399 · Cited by 306
Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma
Jeng, Y.-M., Peng, S.-Y., Lin, C.-Y., & Hsu, H.-C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1057-03 · Cited by 304
Targeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
Koschmann, C., Calinescu, A.-A., Nunez, F. J., Mackay, A., Fazal-Salom, J., Thomas, D., Mendez, F., Kamran, N., Dzaman, M., Mulpuri, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8228 · Cited by 290
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
Thorburn, A., Thamm, D. H., & Gustafson, D. L. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.091850 · Cited by 280
Emerging strategies to effectively target autophagy in cancer
Rebecca, V. W., & Amaravadi, R. K. (2016) · Oncogene · doi:10.1038/onc.2015.99 · Cited by 278
Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
Altan, N., Chen, Y., Schindler, M., & Simon, S. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1583 · Cited by 265
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Yang, Y.-P., Chien, Y., Chiou, G.-Y., Cherng, J.-Y., Wang, M.-L., Lo, W.-L., Chang, Y.-L., Huang, P.-I., Chen, Y.-W., Shih, Y.-H., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.071 · Cited by 240
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
Wnt signaling in stem and cancer stem cells
Wend, P., Holland, J. D., Ziebold, U., & Birchmeier, W. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2010.09.004 · Cited by 237
Kahlert, U. D., Maciaczyk, D., Doostkam, S., Orr, B. A., Simons, B., Bogiel, T., Reithmeier, T., Prinz, M., Schubert, J., Niedermann, G., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.024 · Cited by 231
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Ochoa, M. C., Minute, L., Rodriguez, I., Garasa, S., Perez‐Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.6 · Cited by 230
Wickström, M., Dyberg, C., Milosevic, J., Einvik, C., Calero, R., Sveinbjörnsson, B., Sandén, E., Darabi, A., Siesjö, P., Kool, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9904 · Cited by 229
Mimeault, M., Hauke, R., Mehta, P. P., & Batra, S. K. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00088.x · Cited by 212
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
Shea, A., Harish, V., Afzal, Z., Chijioke, J., Kedir, H., Dusmatova, S., Roy, A., Ramalinga, M., Harris, B., Blancato, J., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.775 · Cited by 209
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Lu, Y., Kwintkiewicz, J., Liu, Y., Tech, K., Frady, L. N., Su, Y.-T., Bautista, W., Moon, S. I., MacDonald, J., Ewend, M. G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2773 · Cited by 201
Jang, J., Wang, Y., Kim, H.-S., Lalli, M. A., & Kosik, K. S. (2014) · Stem Cells · doi:10.1002/stem.1764 · Cited by 198
Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M., Gónzalez, B., & Melguizo, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140131 · Cited by 198
DNA repair mechanisms and their clinical impact in glioblastoma
Erasimus, H., Gobin, M., Niclou, S., & Van Dyck, E. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.05.005 · Cited by 188
Mizoguchi, M., Betensky, R. A., Batchelor, T. T., Bernay, D. C., Louis, D. N., & Nutt, C. L. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000248549.14962.b2 · Cited by 171
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Xue, S., Hu, M., Iyer, V., & Yu, J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0455-6 · Cited by 168
Ardon, H., Van Gool, S. W., Verschuere, T., Maes, W., Fieuws, S., Sciot, R., Wilms, G., Demaerel, P., Goffin, J., Van Calenbergh, F., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1261-1 · Cited by 165
Comincini, S., Allavena, G., Palumbo, S., Morini, M., Durando, F., Angeletti, F., Pirtoli, L., & Miracco, C. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24597 · Cited by 163
Redox Regulation in Cancer Stem Cells
Ding, S., Li, C., Cheng, N., Cui, X., Xu, X., & Zhou, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/750798 · Cited by 161
Zhou, A., Lin, K., Zhang, S., Chen, Y., Zhang, N., Xue, J., Wang, Z., Aldape, K., Xie, K., Woodgett, J. R., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3396 · Cited by 161
Giladi, M., Munster, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Blat, R., Zielinska-Chomej, K., Hååg, P., Bomzon, Z., Kirson, E. D., et al. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0941-6 · Cited by 159
Bobustuc, G. C., Baker, C. H., Limaye, A., Jenkins, W. D., Pearl, G. S., Avgeropoulos, N. G., & Konduri, S. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq044 · Cited by 156
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide
Kanzawa, T., Bedwell, J. R., Kondo, Y., Kondo, S., & Germano, I. M. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.6.1047 · Cited by 155
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
Garros-Regulez, L., Aldaz, P., Arrizabalaga, O., Moncho-Amor, V., Carrasco‐García, E., Manterola, L., Moreno‐Cugnon, L., Barrena, C., Villanúa, J., Ruiz, I., et al. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1151002 · Cited by 151
Inogés, S., Tejada, S., de Cerio, A. L.-D., Pérez‐Larraya, J. G., Espinós, J., Idoate, M. A., Domínguez, P. D., de Eulate, M. R. G., Aristu, J., Bendandi, M., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1202-z · Cited by 143
Li, L., Quang, T. S., Gracely, E., Kim, J. H., Emrich, J., Yaeger, T. E., Jenrette, J. M., Cohen, S. C., Black, P., & Brady, L. W. (2010) · Journal of neurosurgery · doi:10.3171/2010.2.jns091211 · Cited by 139
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S., & Menck, C. F. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10129 · Cited by 135
Immunotherapies for malignant glioma
Boussiotis, V. A., & Charest, A. (2017) · Oncogene · doi:10.1038/s41388-017-0024-z · Cited by 135
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 134
Targeting SOX2 as a Therapeutic Strategy in Glioblastoma
Garros-Regulez, L., García, I., Carrasco‐García, E., Lantero, A., Aldaz, P., Moreno‐Cugnon, L., Arrizabalaga, O., Undabeitia, J. I., Torres-Bayona, S., Villanúa, J., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00222 · Cited by 131
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme
Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1151 · Cited by 131
Satō, A., Sunayama, J., Matsuda, K., Seino, S., Suzuki, K., Watanabe, E., Tachibana, K., Tomiyama, A., Kayama, T., & Kitanaka, C. (2011) · Stem Cells · doi:10.1002/stem.753 · Cited by 128
Mathieu, V., Nève, N. D., Mercier, M. L., Dewelle, J., Gaussin, J., Dehoux, M., Robert Kiss, A., & Lefranc, F. (2008) · Neoplasia · doi:10.1593/neo.08928 · Cited by 124
Florian, B.-A., Lamure, M. P., Ducray, F., Aulagner, G., Honnorat, J., & Armoiry, X. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now102 · Cited by 120
Yu, Z., Xie, G., Zhou, G., Cheng, Y., Zhang, G., Yao, G., Chen, Y., Li, Y., & Zhao, G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.007 · Cited by 117
Yu, Z., Zhao, G., Xie, G., Zhao, L., Chen, Y., Yu, H., Zhang, Z., Li, C., & Li, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5405 · Cited by 106
Hirst, T. C., Vesterinen, H. M., Sena, E. S., Egan, K. J., Macleod, M. R., & Whittle, I. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.504 · Cited by 106
Tateishi, K., Higuchi, F., Miller, J. J., Koerner, M. V. A., Lelic, N., Shankar, G. M., Tanaka, S., Fisher, D. E., Batchelor, T. T., Iafrate, A. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2263 · Cited by 101
Self-citationGlioma Formation, Cancer Stem Cells, and Akt Signaling
Hambardzumyan, D., Squatrito, M., Carbajal, E., & Holland, E. C. (2008) · Stem Cell Reviews and Reports · doi:10.1007/s12015-008-9021-5 · Cited by 100
Sox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade Oligodendroglioma
Favaro, R., Appolloni, I., Pellegatta, S., Sanga, A. B., Pagella, P., Gambini, E., Pisati, F., Ottolenghi, S., Foti, M., Finocchiaro, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1942 · Cited by 99
Dose‐dense temozolomide regimens
Neyns, B., Tosoni, A., Hwu, W., & Reardon, D. A. (2010) · Cancer · doi:10.1002/cncr.25035 · Cited by 98
Xue, S., Hu, M., Li, P., Ma, J., Xie, L., Teng, F., Zhu, Y., Fan, B., Mu, D., & Yu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17922 · Cited by 98
Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene.
Harris, L. C., Remack, J. S., Houghton, P. J., & Brent, T. P. (1996) · PubMed · Cited by 95
Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
Matsuda, K., Satō, A., Okada, M., Shibuya, K., Seino, S., Suzuki, K., Watanabe, E., Narita, Y., Shibui, S., Kayama, T., et al. (2012) · Scientific Reports · doi:10.1038/srep00516 · Cited by 95
Hägerstrand, D., He, X., Lindh, M. B., Hoefs, S., Hesselager, G., Östman, A., & Nistér, M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor113 · Cited by 93
Weller, M., Butowski, N. A., Tran, D. D., Recht, L. D., Lim, M. K., Hirte, H. W., Ashby, L. S., Mechtler, L., Goldlust, S. A., IWAMOTO, F. M., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now212.068 · Cited by 88
Valtorta, S., Dico, A. L., Raccagni, I., Gaglio, D., Belloli, S., Politi, L. S., Martelli, C., Diceglie, C., Bonanomi, M., Ercoli, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23028 · Cited by 86
Yuen, C., Asuthkar, S., Guda, M. R., Tsung, A. J., & Velpula, K. K. (2016) · CNS Oncology · doi:10.2217/cns-2015-0006 · Cited by 85
Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in glioma
Zou, Y., Wang, Q., Li, B., Xie, B., & Wang, W. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2151 · Cited by 83
Wong, H. K., Fatimy, R. E., Onodera, C. S., Wei, Z., Yi, M., Mohan, A., Gowrisankaran, S., Karmali, P. P., Marcusson, E. G., Wakimoto, H., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.72 · Cited by 81
Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
Bregy, A., Wong, T. M., Shah, A. H., Goldberg, J. M., & Komotar, R. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.007 · Cited by 78
Zhang, S., Wan, Y., Pan, T., Gu, X., Qian, C., Sun, G., Sun, L., Xiang, Y., Wang, Z., & Shi, L. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9759-8 · Cited by 74
Han, B. R., Cai, J., Gao, W., Meng, X., Gao, F., Wu, P., Duan, C., Wang, R., Dinislam, M., Lin, L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.056 · Cited by 74
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma
del Alcazar, C. R. G., Todorova, P. K., Habib, A. A., Mukherjee, B., & Burma, S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0125 · Cited by 73
Lehman, N. L., O’Donnell, J. P., Whiteley, L. J., Stapp, R., Lehman, T. D., Roszka, K. M., Schultz, L. R., Williams, C. J., Mikkelsen, T., Brown, S. L., et al. (2012) · Cell Cycle · doi:10.4161/cc.11.3.18996 · Cited by 71
Pyko, I. V., Nakada, M., Sabit, H., Teng, L., Furuyama, N., Hayashi, Y., Kawakami, K., Minamoto, T., Fedulau, A., & Hamada, J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt182 · Cited by 71
Self-citationGilbert, M. R., Pugh, S. L., Aldape, K. D., Sorensen, A. G., Mikkelsen, T., Peñas-Prado, M., Bokstein, F., Kwok, Y., Lee, R. J., & Mehta, M. P. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2288-5 · Cited by 70
Dendritic cells and tumor immunity
Gunzer, M., Jänich, S., Varga, G., & Grabbe, S. (2001) · Seminars in Immunology · doi:10.1006/smim.2001.0325 · Cited by 69
Repair mechanisms help glioblastoma resist treatment
Atkins, R. J., Ng, W., Stylli, S. S., Hovens, C. M., & Kaye, A. H. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.09.003 · Cited by 69
Narayan, R. S., Fedrigo, C. A., Brands, E., Dik, R., Stalpers, L. J. A., Baumert, B. G., Slotman, B. J., Westerman, B. A., Peters, G. J., & Sminia, P. (2017) · BMC Cancer · doi:10.1186/s12885-017-3193-9 · Cited by 67
Metformin treatment reduces temozolomide resistance of glioblastoma cells
Yang, S. H., Li, S., Lu, G., Xue, H., Kim, D., Zhu, J., & Liu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12859 · Cited by 66
Akasaki, Y., Kikuchi, T., Homma, S., Koido, S., Ohkusa, T., Tasaki, T., Hayashi, K., Komita, H., Watanabe, N., Suzuki, Y., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1905-7 · Cited by 65
Wakabayashi, T., Natsume, A., Mizusawa, J., Katayama, H. G., Fukuda, H., Sumi, M., Nishikawa, R., Narita, Y., Muragaki, Y., Maruyama, T., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2831-7 · Cited by 64
The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
Okada, M., Kuramoto, K., Takeda, H., Watarai, H., Sakaki, H., Seino, S., Seino, M., Suzuki, S., & Kitanaka, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8395 · Cited by 63
Natsume, A., Wakabayashi, T., Ishii, D., Maruta, H., Fujii, M., Shimato, S., Ito, M., & Yoshida, J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0520-x · Cited by 62
Kawasaki, Y., Ishigami, S., Arigami, T., Uenosono, Y., Yanagita, S., Uchikado, Y., Kita, Y., Nishizono, Y., Okumura, H., Nakajo, A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1008-4 · Cited by 62
The strategy for enhancing temozolomide against malignant glioma
Nakada, M., Furuta, T., Hayashi, Y., Minamoto, T., & Hamada, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00098 · Cited by 62
Self-citationAn update on vaccine therapy and other immunotherapeutic approaches for glioblastoma
Reardon, D. A., Wucherpfennig, K. W., Freeman, G. J., Wu, C. J., Chiocca, E. A., Wen, P. Y., Curry, W. T., Mitchell, D. A., Fecci, P. E., Sampson, J. H., et al. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.41 · Cited by 62
Koschmann, C. J., Lowenstein, P. R., & Castro, M. G. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1167158 · Cited by 61
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Peters, K. B., Lipp, E., Miller, E., Herndon, J. E., McSherry, F., Desjardins, A., Reardon, D. A., & Friedman, H. S. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2724-1 · Cited by 59
Okada, M., Satō, A., Shibuya, K., WATANABE, E., Seino, S., Suzuki, S., Seino, M., Narita, Y., Shibui, S., Kayama, T., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2209 · Cited by 57
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
Tian, T., Mingyi, M., Qiu, X., & Qiu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12861 · Cited by 56
Zhang, L., & Wang, H. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.07.003 · Cited by 55
Yu, Z., Zhao, G., LI, P., Li, Y., Zhou, G., Chen, Y., & Xie, G. (2016) · Oncology Letters · doi:10.3892/ol.2016.4315 · Cited by 54
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
Kim, E. S., Kim, J. E., Patel, M. A., Mangraviti, A., Ruzevick, J., & Lim, M. K. (2016) · Journal of Immunology Research · doi:10.1155/2016/4683607 · Cited by 53
Jung (2010) · Oncology Reports · doi:10.3892/or_00000760 · Cited by 52
Furuta, T., Sabit, H., Dong, Y. J., Miyashita, K., Kinoshita, M., Uchiyama, N., Hayashi, Y., Hayashi, Y., Minamoto, T., & Nakada, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15206 · Cited by 51
Self-citationMicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53
Zhou, X., Wu, W., Zeng, A., Nie, E., Jin, X., Yu, T., Zhi, T., Jiang, K., Wang, Y., Zhang, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20528 · Cited by 51
The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness
Gao, X., & Jin, W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.011 · Cited by 50
Current evidence of temozolomide and bevacizumab in treatment of gliomas
Nanegrungsunk, D., Onchan, W., Chattipakorn, N., & Chattipakorn, S. C. (2014) · Neurological Research · doi:10.1179/1743132814y.0000000423 · Cited by 50
Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms
Cruceru, M. L., Neagu, M. T., Demoulin, J., & Constantinescu, S. N. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12122 · Cited by 49
Tso, J. L., Yang, S., Menjivar, J. C., Yamada, K., Zhang, Y., Hong, I., Bui, Y., Stream, A., McBride, W. H., Liau, L. M., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0459-1 · Cited by 49
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme
Oberstadt, M. C., Bien-Möller, S., Weitmann, K., Herzog, S., Hentschel, K., Rimmbach, C., Vogelgesang, S., Balz, E., Fink, M. A., Michael, H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-617 · Cited by 48
Emerging immunotherapies for glioblastoma
Desai, R. R., Suryadevara, C. M., Batich, K. A., Farber, S. H., Sanchez-Perez, L. A., & Sampson, J. H. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186643 · Cited by 46
Song, Y., Chen, Y., Li, Y., Xiaoyan, L., Cui, J., Cheng, Y., Zhao, L., & Zhao, G. (2017) · Oncotarget · doi:10.18632/oncotarget.23317 · Cited by 46
López‐Ginés, C., Gil‐Benso, R., Benito, R., Mata, M., Pereda, J., Sastre, J., Roldán, P., Gonzalez-Darder, J. M., & Cerdá‐Nicolás, M. (2008) · Neuropathology · doi:10.1111/j.1440-1789.2008.00911.x · Cited by 43
Chen, P.-H., Cheng, C.-H., Shih, C.-M., Ho, K.-H., Lin, C.-W., Lee, C.-C., Liu, A.-J., Chang, C.-K., & Chen, K.-C. (2016) · PLOS ONE · doi:10.1371/journal.pone.0167096 · Cited by 41
The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
Shi, F., Zhang, J., Liu, H., Wu, L., Jiang, H., Wu, Q., Liu, T., Lou, M., & Wu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.23091 · Cited by 41
Autophagy Regulators as Potential Cancer Therapeutic agents: A Review
Li, S., Wang, L., Hu, Y., & Sheng, R. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150302105343 · Cited by 40
Wei, W., Chen, X., Ma, X., Wang, D., & Guo, Z. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1920-0 · Cited by 34
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells
Hayashi, T., Adachi, K., Ohba, S., & Hirose, Y. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1220-5 · Cited by 34
Glioma Stem Cells: Their Role in Chemoresistance
Yamada, R., & Nakano, I. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2012.01.004 · Cited by 29
Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme
Heynckes, S., Gaebelein, A., Haaker, G., Grauvogel, J., Franco, P., Mader, I., Carro, M. S., Prinz, M., Delev, D., Schnell, O., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18819 · Cited by 28
A silver lining on the horizon for glioblastoma
Knisely, J. P. S., & Baehring, J. M. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70124-x · Cited by 25
Motta, C., D’Angeli, F., Scalia, M., Satriano, C., Barbagallo, D., Николаевна, Н. И., Anfuso, C. D., Lupo, G., & Spina-Purrello, V. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.04.026 · Cited by 21
Koul, D., Wang, S., Wu, S., Saito, N., Zheng, S., Gao, F., Kaul, I., Setoguchi, M., Nakayama, K., Koyama, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15566 · Cited by 21
Dose-dense Temozolomide: Is It Still Promising?
Nagane, M. (2014) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2014-0277 · Cited by 19
Xu, J., Huang, H., Peng, R., Ding, X., Jiang, B., Yuan, X., & Xi, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6007 · Cited by 18
The progress of immunotherapy for glioblastoma
Zhou, Q., Wang, Y., & Ma, W. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1081727 · Cited by 11
Tabatabai, G., Wick, W., Steinbach, J. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2015 · Cited by 9
Park, J., Kwon, M., Kim, K. H., Chang, J. H., & Shin, E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.198.supp.196.3 · Cited by 7
Cited by
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Prognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 340
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Li, H., Liu, S., Jin, R., Xu, H., Li, Y., Chen, Y., & Zhao, G. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00654-2 · Cited by 34
Metadata
- Authors
- JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M.
- Venue
- Neurologia medico-chirurgica
- Publisher
- Japan Neurosurgical Society
- Published
- 2018
- Volume
- 58
- Issue
- 10
- Pages
- 405-421
- ISSN
- 0470-8105 (ISSN-L)
- 1349-8029
- OpenAlex
- W2890744696
- Cited by
- 324
- References
- 151
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.